Mouse models of human neurodegenerative disorders: Requirements for medication development

Floyd E. Bloom, John F. Reilly, Jeff M. Redwine, Chi Cheng Wu, Warren G. Young, John Morrison

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalArchives of Neurology
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Mouse models of human neurodegenerative disorders: Requirements for medication development'. Together they form a unique fingerprint.

  • Cite this